We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-10.34%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.95B
AUM Growth
-$1.05B
Cap. Flow
+$64.3M
Cap. Flow %
1.08%
Top 10 Hldgs %
34.22%
Holding
172
New
36
Increased
33
Reduced
28
Closed
30

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$126M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$126M
3
PASG icon
Passage Bio
PASG
+$109M
4
PFE icon
Pfizer
PFE
+$108M
5
CNC icon
Centene
CNC
+$81M

Top Sells

Rank Stock Value
1
THOR
Synthorx, Inc. Common Stock
THOR
+$372M
2
ARQL
Arqule Inc
ARQL
+$99.8M
3
DHR icon
Danaher
DHR
+$98.1M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$79.2M
5
INSP icon
Inspire Medical Systems
INSP
+$74M

Sector Composition

Rank Sector Weight
1 Healthcare 96.88%
2 Financials 1.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EPIX
101
DELISTED
ESSA Pharma
EPIX
$5.89M 0.1%
1,471,853
– –
TXG icon
102
10x Genomics
TXG
$5.84B
$5.78M 0.1%
+92,700
New +$7.23M
ARNA
103
DELISTED
Arena Pharmaceuticals Inc
ARNA
$5.6M 0.09%
133,400
+23,400
+21% +$1.07M
ANAB icon
104
AnaptysBio
ANAB
$1.51B
$5.31M 0.09%
375,800
– –
VRNA
105
DELISTED
Verona Pharma
VRNA
$5.15M 0.09%
1,250,396
– –
ACET icon
106
Adicet Bio
ACET
$76M
$4.97M 0.08%
43,128
– –
TBPH icon
107
Theravance Biopharma
TBPH
$875M
$4.89M 0.08%
+211,545
New +$5.29M
HCAT icon
108
Health Catalyst
HCAT
$157M
$4.7M 0.08%
179,598
– –
VYNE icon
109
VYNE Therapeutics
VYNE
$4.69M 0.08%
+486
New +$7.62M
IGMS
110
DELISTED
IGM Biosciences
IGMS
$4.54M 0.08%
+80,760
New +$3.54M
IFRX icon
111
InflaRx
IFRX
$243M
$4.08M 0.07%
+1,067,600
New +$3.95M
APTO
112
DELISTED
Aptose Biosciences, Inc.
APTO
$3.91M 0.07%
1,464
-1,092
-43% -$3.26M
ARGX icon
113
argenx
ARGX
$55B
$3.77M 0.06%
28,591
-227,709
-89% -$33.3M
SYBX
114
DELISTED
Synlogic
SYBX
$3.49M 0.06%
135,333
– –
TRIL
115
DELISTED
Trillium Therapeutics Inc.
TRIL
$3.24M 0.05%
+801,000
New +$3.03M
KALV
116
DELISTED
KalVista Pharmaceuticals
KALV
$3.22M 0.05%
420,641
+260,100
+162% +$3.51M
NTLA icon
117
Intellia Therapeutics
NTLA
$1.49B
$3.21M 0.05%
262,100
– –
SNDX icon
118
Syndax Pharmaceuticals
SNDX
$1.67B
$3.18M 0.05%
290,000
+78,000
+37% +$732K
WHWK
119
Whitehawk Therapeutics
WHWK
$180M
$2.86M 0.05%
346,263
– –
IMVT icon
120
Immunovant
IMVT
$7.76B
$2.79M 0.05%
+179,500
New +$2.7M
NBRV
121
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$2.67M 0.04%
18,578
– –
NBSE
122
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$2.64M 0.04%
+18,556
New +$2.46M
ISEE
123
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$2.58M 0.04%
750,000
-250,000
-25% -$1.46M
APTX
124
DELISTED
Aptinyx Inc. Common Stock
APTX
$2.51M 0.04%
1,162,108
+1,019,108
+713% +$3.33M
BTAI icon
125
BioXcel Therapeutics
BTAI
$24.8M
$2.4M 0.04%
+6,706
New +$2.41M
3 4
5
6 7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q1 2020 Portfolio in Review

As of Q1 2020, OrbiMed held 172 positions worth $5.95B, down 15% from $7B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed's Q1 2020 filing shows 36 new, 33 increased, 28 reduced and 30 closed positions. Its largest new stake was Arcutis Biotherapeutics: 4,673,850 shares worth $139M. The largest sale was Synthorx, Inc. Common Stock, an estimated $372M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q1 2020 buy was Arcutis Biotherapeutics: 4,673,850 shares worth $139M.
  • OrbiMed added most to Biogen in Q1 2020, an estimated $126M increase.
  • OrbiMed's biggest Q1 2020 reduction was Regeneron Pharmaceuticals, cutting an estimated $79.2M.
  • OrbiMed fully exited Synthorx, Inc. Common Stock in Q1 2020, selling an estimated $372M.
  • OrbiMed's ten largest holdings make up 34% of its $5.95B portfolio in Q1 2020.
  • OrbiMed opened 36 new positions and closed 30 in Q1 2020.
  • OrbiMed's portfolio value fell 15% quarter-over-quarter to $5.95B.

Based on OrbiMed's 13F filing for Q1 2020, filed 15 May 2020.